BII allocates 8 million euros to further support six promising companies
Six promising companies are receiving additional funding from BioInnovation Institute (BII). With convertible loans of EUR 1.3M each, the companies will bring their technologies and products closer to market.
BioInnovation Institute (BII) today announces that six promising companies will receive additional funding of EUR 1.3M each. The new funding will help the companies mature their technologies, strengthen their businesses and take the next steps towards commercial application.
The six companies – PanTarg, 3Sonic, Inia Biosciences, Yngvi Bio, Proxi Biotech and Sagava – have all previously received EUR 0.5M in funding from BII. With the new funds allocated, each company has now received a total of EUR 1.8 million from BII.
The continued funding also comes with access to BII’s internationally recognized innovation platform in the heart of Copenhagen. Here, the companies gain access to advanced laboratory facilities, a global network of investors, advisors and strategic partners, as well as expertise in business development and commercialisation.
According to Trine Bartholdy, Chief Business Officer at BII, the companies have now reached an important stage in their development.
“The six companies have demonstrated strong potential and have already taken important steps from promising research to developing solutions that can make a real difference. With continued funding, they have the opportunity to accelerate their development and focus even more on their path towards the market.”
BII’s ambition is not only to provide funding, but also to give the companies the right framework and expertise to develop into strong, international businesses.
“It is precisely at this stage that the combination of capital, strong expertise and the right network can make a decisive difference. We see significant potential in all six companies, and our role is to help them turn their technologies into sustainable businesses and products that can create value for patients, society and investors,” says Trine Bartholdy.
With the new funding, the six companies are better positioned to further develop their technologies, attract additional external capital and bring their solutions closer to commercial market application.
The six companies receiving additional financial support from BII are:
PanTarg
PanTarg is developing a new type of antibody-based cancer treatment that combines two targeted attacks in a single therapy. The company’s technology is particularly aimed at aggressive cancers, including pancreatic cancer, where there remains a significant need for more effective treatments. PanTarg is a spin-out from the University of Copenhagen and Rigshospitalet, founded by researchers Lars H. Engelholm and Virginia Metrangolo. The company is also a partner in a major research project for the period 2026–2030, supported by the Innovation Fund Denmark, focusing on enabling drugs to cross the blood-brain barrier.
3Sonic
3Sonic is developing a new imaging technology based on 3D ultrasound and artificial intelligence, designed to enable surgeons to assess cancer tissue in real time during surgery. The aim is to increase the precision of cancer surgery and improve patient outcomes. 3Sonic is a spin-out from Rigshospitalet and the Technical University of Denmark (DTU).
Inia Biosciences
Inia Biosciences is developing new treatments for inflammatory diseases, with psoriasis as its initial focus. The company is working to transform the treatment of inflammation and develop more effective therapeutic solutions for patients suffering from inflammatory diseases. Inia Biosciences originally emerged from the innovation ecosystems in Boston and Oxford.
Yngvi Bio
Yngvi Bio is developing biological solutions to combat agricultural pests. Through targeted pest control, the company aims to protect crops while reducing the impact on biodiversity, the environment and human health. The goal is to contribute to a more sustainable food production system. Yngvi Bio is a spin-out from the University of Copenhagen.
Proxi Biotech
Proxi Biotech is developing a novel vaccine-based immunotherapy for recurrent bacterial infections. The company’s lead candidate targets recurrent infections caused by Clostridium difficile, which can affect patients repeatedly and become chronic. The technology is intended to provide an alternative to treatments such as faecal microbiota transplantation.
Sagava
Sagava is working to reduce CO₂ emissions from the maritime sector by converting waste into sustainable biofuels and energy. The company’s technology aims to help decarbonise shipping by utilising waste resources to produce biogenic fuels. Sagava is a spin-out from the Technical University of Denmark (DTU).
